MedTrace Logo

Azithromycin for COVID-19 Treatment in Outpatients Nationwide

NCT04332107 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 263

Last updated 2023-03-02

Study results available
· View outcomes & findings →

Summary

This individually randomized telemedicine-based trial aims to evaluate the efficacy of a single dose of azithromycin for prevention of progression of COVID-19 in patients with a recent positive SARS-CoV-2 test who are not currently hospitalized.

Conditions

Interventions

DRUG

Azithromycin

Participants will be shipped a single 1.2 g dose of oral azithromycin

DRUG

Placebos

Participants will be shipped a dose of matching placebo

Sponsors & Collaborators

  • Bill and Melinda Gates Foundation

    collaborator OTHER

  • Pfizer

    collaborator INDUSTRY

  • Stanford University

    collaborator OTHER

  • Thomas M. Lietman

    lead OTHER

Principal Investigators

  • Catherine Oldenburg, ScD, MPH · University of California, San Francisco

  • Thuy Doan, MD, PhD · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-22
Primary Completion
2021-03-16
Completion
2021-03-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04332107 on ClinicalTrials.gov